Skip to main content
Journal cover image

Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.

Publication ,  Journal Article
Liu, Z; Guo, BL; Gehrs, BC; Nan, L; Lopez, RD
Published in: J Urol
May 2005

PURPOSE: We have previously identified a CD2 mediated, interleukin-12 dependent signaling pathway that inhibits activation induced cell death in mitogen stimulated human gammadelta-T cells, permitting the large-scale expansion of these cells. Herein we report the innate antitumor activity of expanded human Vgamma9Vdelta2+ gammadelta-T cells against human prostate cancer cells. MATERIALS AND METHODS: Apoptosis resistant human gammadelta-T cells were expanded in vitro from cultured human peripheral blood mononuclear cells and then enriched to high purity by immunomagnetic separation. In vitro cytotoxicity of expanded gammadelta-T cells was measured against human prostate cancer cell lines using standard cytotoxicity assays. RESULTS: gammadelta-T cells derived from various donors consistently showed lytic activity against the prostate cancer cell lines DU-145 and PC-3 but not LNCaP. mAbs against Vgamma9 or Vdelta2 T-cell receptor chains as well as mAb against intercellular adhesion molecule-1 (ICAM-1) or CD18, the beta subunit of ICAM-1 counter receptors, blocked gammadelta-T cell mediated killing of prostate cancer cells. gammadelta-T cells lysed prostate cancer cell lines largely through the perforin/granzyme pathway. CONCLUSIONS: Ex vivo, expanded human Vgamma9Vdelta2+ gammadelta-T cells are able innately to recognize and kill certain human prostate tumor cell lines in vitro. The recognition and killing of prostate cancer cells occurs in a gammadelta-T-cell receptor dependent manner and it also appears to involve interactions between ICAM-1 and CD18. Because apoptosis resistant human Vgamma9Vdelta2+ gammadelta-T cells can readily be expanded to large numbers (clinical scale), these findings must be considered in the context of developing adoptive immunotherapy strategies to exploit gammadelta-T cell innate immune responses to prostate cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

May 2005

Volume

173

Issue

5

Start / End Page

1552 / 1556

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tumor Cells, Cultured
  • T-Lymphocytes
  • Receptors, Antigen, T-Cell, gamma-delta
  • Prostatic Neoplasms
  • Male
  • Humans
  • Drug Screening Assays, Antitumor
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liu, Z., Guo, B. L., Gehrs, B. C., Nan, L., & Lopez, R. D. (2005). Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol, 173(5), 1552–1556. https://doi.org/10.1097/01.ju.0000154355.45816.0b
Liu, Zhiyong, Ben L. Guo, Bradley C. Gehrs, Li Nan, and Richard D. Lopez. “Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.J Urol 173, no. 5 (May 2005): 1552–56. https://doi.org/10.1097/01.ju.0000154355.45816.0b.
Liu, Zhiyong, et al. “Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.J Urol, vol. 173, no. 5, May 2005, pp. 1552–56. Pubmed, doi:10.1097/01.ju.0000154355.45816.0b.
Journal cover image

Published In

J Urol

DOI

ISSN

0022-5347

Publication Date

May 2005

Volume

173

Issue

5

Start / End Page

1552 / 1556

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tumor Cells, Cultured
  • T-Lymphocytes
  • Receptors, Antigen, T-Cell, gamma-delta
  • Prostatic Neoplasms
  • Male
  • Humans
  • Drug Screening Assays, Antitumor
  • 3202 Clinical sciences
  • 1103 Clinical Sciences